Preclinical Capabilities
Cell Therapy/Immuno-Oncology Preclinical Models
Trusted immune-oncology models for optimal CAR-T study design
TD2 is your trusted, experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy studies. Our extensive knowledge of CAR-T in both solid and hematologic tumors enables optimal study design and rapid study initiation.
Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Having performed hundreds of studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.
TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability.
Cell Therapy Capabilities of 400+ Cell line derived xenograft (CDX) models include:
- Optical imaging (Bioluminescence and Fluorescence)
- Orthotopic and surgical
- IP Dissemination
- IV Dissemination
- Hematological
- Biodistribution
- Non-GLP Toxicity
Learn more about our CAR-T services.
Contact our experts to help advance your adoptive cell therapy with our trusted preclinical research services.
Figure A. CAR-T Cell Treatment on subQ Hs7666T
Pancreatic Cell Line. 5 x 106 CAR-T Cells given on Day 1
Figure B. CAR-T Cell Treatment on IV disseminated
Nalm-6-luc ALL Cell Line. 4 x106 CAR-T Cells given on Day 4
Available Cell Lines
TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR-T cell mouse studies across multiple antigen targets in a number of oncology indications.
-
Dr. Jon Terrett Head of Immuno-Oncology Research and Translation CRISPR Therapeutics
IMMUNO-ONCOLOGY
Comprehensive preclinical services for immuno-oncology.
TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.
Large panel of human and murine tumor models
- Fully characterized for gene expression, TIL baseline populations, and response to common immune checkpoint inhibitors
Humanized mice
- Human PBMCs or effector cell engraftment
- Sourced CD34+ humanized mice
- Humanized immune checkpoint inhibitor mice
